Technical analysis of Kyverna Therapeutics, Inc. (KYTX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis.
Price Performance
| 1 month | -18.94% |
| 3 months | -14.62% |
| Year-to-date | -26.70% |
| 1 year | +57.67% |
52-Week Range
| 52-week High | $13.67 |
| 52-week Low | $3.85 |
| Avg Volume (90d) | 949K |
Technical Indicators
| SMA 50 | $7.97 |
| SMA 200 | $8.42 |
| Beta | 2.64 |
| 30-day Volatility (annualised) | 59.3% |
| Price vs SMA 50 | -13.6% |
| Price vs SMA 200 | -18.2% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $6.97 | |
| 2025-11 | $7.67 | +10.0% |
| 2025-12 | $9.40 | +22.6% |
| 2026-01 | $8.01 | -14.8% |
| 2026-02 | $8.21 | +2.5% |
| 2026-03 | $8.63 | +5.1% |
| 2026-04 | $8.80 | +2.0% |
| 2026-05 | $8.52 | -3.2% |
| 2026-06 | $8.91 | +4.6% |
| 2026-07 | $7.30 | -18.1% |
| 2026-08 | $8.48 | +16.2% |
| 2026-09 | $6.89 | -18.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $6.90 |
| Market Cap | $419M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.39 |
| EV / EBITDA | -2.96 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.20 |
| Current Ratio | 9.06 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 1.13 |